Table 4.
Factors Affecting Clinical Remission with Adalimumab Treatment Identified by Multiple Logistic Regression with As-Observed Analysis (n=1,037)
| Baseline factor | No. of patients evaluated | OR (95% CI) |
|---|---|---|
| Age (yr) | ||
| < 15 | 12 | 1.76 (0.46–6.78) |
| 15 to < 65 | 926 | NA |
| ≥ 65 | 99 | 1.05 (0.67–1.64) |
| Body weight (kg) | ||
| < 30 | 1 | NA |
| 30 to < 40 | 34 | 0.63 (0.29–1.37) |
| 40 to < 50 | 248 | 1.16 (0.82–1.63) |
| 50 to < 60 | 371 | NA |
| ≥ 60 | 383 | 0.94 (0.69–1.27) |
| Disease duration (yr) | ||
| <2 | 214 | 0.66 (0.47–0.94) |
| 2 to < 10 | 516 | NA |
| ≥ 10 | 307 | 1.53 (1.12–2.07) |
| Prior use of biologics | ||
| No | 762 | NA |
| Yes | 275 | 0.58 (0.43–0.79) |
| Prior use of tacrolimus/cyclosporine | ||
| No | 839 | NA |
| Yes | 198 | 0.67 (0.49–0.94) |
| History of surgical operation | ||
| No | 1,029 | NA |
| Yes | 8 | 3.86 (0.45–33.15) |
| Concomitant use of corticosteroid | ||
| No | 560 | NA |
| Yes | 477 | 0.98 (0.75–1.28) |
| Concomitant use of immunomodulator | ||
| No | 578 | NA |
| Yes | 459 | 0.98 (0.75–1.27) |
| Montreal classification | ||
| Proctitis | 25 | 1.29 (0.55–3.02) |
| Left-sided colitis | 307 | 1.05 (0.79–1.40) |
| Extensive colitis | 705 | NA |
| Partial Mayo score | ||
| 0 to < 3 | 139 | 3.50 (2.25–5.43) |
| 3 to < 6 | 402 | 1.60 (1.21–2.12) |
| 6 to ≤ 9 | 496 | NA |
| Patient hospitalization status | ||
| Inpatient | 360 | NA |
| Outpatient | 677 | 0.52 (0.39–0.69) |
OR, odds ratio; CI, confidence interval; NA, not applicable (control group in each baseline factor category; therefore, no values).